| Ann Sterzinger Raymond, MD | |
|
4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 | |
| (952) 835-9880 | |
| (952) 857-1554 |
| Full Name | Ann Sterzinger Raymond |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 22 Years |
| Location | 4300 Marketpointe Dr Ste 100, Bloomington, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275560690 | NPI | - | NPPES |
| 350418200 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 47376 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Memorial Health | Robbinsdale, MN | Hospital |
| Maple Grove Hospital | Maple grove, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Physicians Professional Association | 9537072657 | 205 |
News Archive
Two important new studies challenge the controversial hypothesis that venous congestion—chronic cerebrospinal venous insufficiency (CCSVI)—contributes to the development of multiple sclerosis (MS). This theory has resulted in many MS patients receiving experimental endovascular angioplasty, a treatment for MS unproven by clinical trials.
Luna Innovations Incorporated (NASDAQ:LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced that the Company has received a letter from The NASDAQ Stock Market indicating that because the bid price of the Company's common stock closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days, the Company has been provided 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.
An expert New Zealand committee reviewing the safety of a group of arthritis drugs called COX-2 inhibitors has reinforced UK advice cautioning against their routine use where safe and effective alternatives are available.
› Verified 9 days ago
| Entity Name | Emergency Physicians Professional Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801871934 PECOS PAC ID: 9537072657 Enrollment ID: O20031106000068 |
News Archive
Two important new studies challenge the controversial hypothesis that venous congestion—chronic cerebrospinal venous insufficiency (CCSVI)—contributes to the development of multiple sclerosis (MS). This theory has resulted in many MS patients receiving experimental endovascular angioplasty, a treatment for MS unproven by clinical trials.
Luna Innovations Incorporated (NASDAQ:LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced that the Company has received a letter from The NASDAQ Stock Market indicating that because the bid price of the Company's common stock closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days, the Company has been provided 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.
An expert New Zealand committee reviewing the safety of a group of arthritis drugs called COX-2 inhibitors has reinforced UK advice cautioning against their routine use where safe and effective alternatives are available.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ann Sterzinger Raymond, MD 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435-5435 Ph: (952) 835-9880 | Ann Sterzinger Raymond, MD 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Ph: (952) 835-9880 |
News Archive
Two important new studies challenge the controversial hypothesis that venous congestion—chronic cerebrospinal venous insufficiency (CCSVI)—contributes to the development of multiple sclerosis (MS). This theory has resulted in many MS patients receiving experimental endovascular angioplasty, a treatment for MS unproven by clinical trials.
Luna Innovations Incorporated (NASDAQ:LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced that the Company has received a letter from The NASDAQ Stock Market indicating that because the bid price of the Company's common stock closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days, the Company has been provided 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.
An expert New Zealand committee reviewing the safety of a group of arthritis drugs called COX-2 inhibitors has reinforced UK advice cautioning against their routine use where safe and effective alternatives are available.
› Verified 9 days ago
Rebecca Lynn Meyer, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 | |
Dr. Holly Lynn Schrupp Berg, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 Fax: 952-857-1554 | |
Andrew H Bauer, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 Fax: 952-857-1554 | |
Laura Kuhlman, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 | |
Elisabeth Marycke Vreede Greenberg, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 Fax: 952-857-1554 | |
Leonardo A Saavedra, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 Fax: 952-857-1554 | |
Dr. Ferris Yeh, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 Fax: 952-857-1554 |